Thank you for sharing!

Your article was successfully shared with the contacts you provided.
An EpiPen set during a House Oversight Committee hearing on Capitol Hill addressing the price increase of the company’s EpiPen product. Photo: Diego M. Radzinschi/ALM

Mylan NV, manufacturer of the lifesaving allergy medication EpiPen, has agreed to pay $30 million in fines to settle charges by the U.S. Securities and Exchange Commission that the company misled investors by making false accounting statements and disclosures about a Justice Department probe into whether the company had overcharged Medicaid by hundreds of millions of dollars, the SEC announced Friday.

MP McQueen

MP McQueen is editor-at-large, and can be reached at mpmcqueen@alm.com

More from this author


Class Actions: The Law of 50 StatesBook

State and federal court class action practitioners alike will find Class Actions: The Law of 50 States to be an invaluable reference tool. Class Action Reports...
Get More Information


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.